Risk of progression of IA after HSCT according to the first AFT given after transplantation as secondary prophylaxis
. | No. patients . | No. patients with progression of IA after allo-HSCT (%) . |
|---|---|---|
| First AFT given after transplantation* | ||
| Azoles (itraconazole/voriconazole) | 93 (50/43) | 24 (26) |
| AmB formulations (c-AmB/ABLC/L-AmB) | 58 (25/11/22) | 19 (33) |
| Caspofungin | 26 | 7 (27) |
| No AFT | 6 | 2 (33) |
| All patients at risk | 129† | 27 (21) |
. | No. patients . | No. patients with progression of IA after allo-HSCT (%) . |
|---|---|---|
| First AFT given after transplantation* | ||
| Azoles (itraconazole/voriconazole) | 93 (50/43) | 24 (26) |
| AmB formulations (c-AmB/ABLC/L-AmB) | 58 (25/11/22) | 19 (33) |
| Caspofungin | 26 | 7 (27) |
| No AFT | 6 | 2 (33) |
| All patients at risk | 129† | 27 (21) |
AmB indicates amphotericin B; and ABLC, AmB lipid complex.
Refers to the AFT used from the time of transplantation as first-line secondary prophylaxis or as second/third-line therapy after toxicity from prior therapy, without progression of the IA.
Forty-eight (37%) patients received more than 1 drug as first-line prophylaxis, either in combination or sequentially.